1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Cambridge Nutritional Sciences PLC

Cambridge Nutritional Sciences PLC

LLSE:CNSL
1.60
GBX
0.00
(0.00%)
440.21MMarket Cap
Nov 19Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
0.11
0.11
0.12
0.13
0.07
0.07
0.07
0.04
0.05
0.03
0.04
0.04
0.03
- -
Basic EPS, GAAP
0.01
0.01
0.01
0.01
-0.06
0.01
-0.05
-0.01
-0.06
-0.02
- -
0.01
-0.02
- -
Free Cash Flow per Basic Share
-0.01
-0.01
-0.01
-0.01
-0.03
-0.02
-0.01
-0.03
-0.03
-0.01
- -
- -
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.17
0.17
0.18
0.19
0.13
0.14
0.09
0.13
0.06
0.04
0.04
0.05
0.02
0.02
Tangible Book Value per Share
0.07
0.06
0.06
0.05
0.02
0.01
0.03
0.07
0.04
0.02
0.02
0.03
0.02
0.02
Basic Weighted Avg Shares
105
110
110
110
123
129
142
172
183
231
238
238
238
238
Sales/Revenue/Turnover
12
12
13
14
8
9
10
7
9
8
10
8
7
- -
Operating Margin (%)
4.55
5.56
5.26
4.88
-14.6
-3.1
7.15
-6.87
-6.93
-35.98
-5.47
-4.74
-13.08
- -
Depreciation Expense
1
1
1
1
1
- -
1
1
1
1
1
1
1
- -
Net Income, GAAP
1
1
1
1
-7
1
-7
-2
-11
-4
- -
2
-6
- -
Effective Tax Rate (%)
- -
- -
13.59
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
5.98
6.11
4.49
5.01
-87.28
11.13
-69.54
-30.87
-132.72
-51.15
-3.36
18.8
-83.53
- -
Working Capital
5
5
4
4
2
1
2
9
7
6
6
6
4
4
LT Debt
- -
- -
- -
- -
1
- -
2
2
- -
- -
- -
- -
- -
- -
Total Equity
18
19
20
21
17
18
14
23
12
10
10
11
6
6
Return on Invested Capital (%)
- -
- -
2.88
- -
- -
- -
- -
- -
- -
- -
- -
-3.69
- -
- -
Return on Capital (%)
- -
- -
2.97
- -
- -
- -
- -
- -
- -
- -
- -
14.67
- -
- -
Return on Common Equity (%)
4.27
3.97
2.93
3.43
-37.69
5.52
-42.95
-11.38
-64.39
-35.47
-3.34
14.85
-68.18
- -

Capital Structure

GBP

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
238
238
238
Market Capitalization
7
7
4

Working Capital

GBP

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
8
7
6
Cash, Cash Equivalents & STI
5
4
3
Accounts Receivable, Net
1
2
2
Inventories
1
1
1
Total Current Liabilities
2
2
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.13%
-20.06%
-50.21%
Free Cash Flow
71.7%
4.23%
357.86%
Net Income, GAAP
-284.62%
-153.65%
-472.03%
Sales/Revenue/Turnover
-3.09%
2.43%
-16.27%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
10
2025
- -
- -
8
2026
- -
- -
7

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
0.01
2026
- -
- -
-0.02

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
James Cooper
Full Time Employees
85
Sector
Health technology
Industry
Medical specialties
Address
One Fleet Place London GL United Kingdom EC4M 7WS
IPO Date
Mar 18, 2004
Website
cnsplc.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Cambridge Nutritional Sciences plc Cambridge Nutritional Sciences plc (AIM: CNSL) is a United Kingdom-based specialist medical diagnostics company that develops, manufactures, and distributes products focused on food sensitivity testing and gut health diagnostics; its core offerings include FoodPrint kits for detecting immune reactions to food via IgG antibody testing, the point-of-care Food Detective self-test kits, CNSLab functional testing services for healthcare professionals and consumers, the My Health Tracker app for symptom tracking and result management, and the newly launched Gut Detective stool biomarker panel assessing gut inflammation, enzyme production, and permeability. The company operates globally across more than 75 countries, serving over 170 laboratories, private clinics, nutritionists, naturopaths, and functional medicine practitioners in regions including the UK, Europe, North America, India, Asia, Africa, and the Middle East. Founded in 2004 and headquartered at Eden Research Park, Henry Crabb Road, Littleport, Cambridge, United Kingdom, the company rebranded from Omega Diagnostics Group PLC in September 2023 to emphasize its nutritional sciences focus. In recent developments, Cambridge Nutritional Sciences completed a sales team restructure in 2025 to separate customer acquisition, service, and success functions aimed at accelerating new distributor and laboratory signings amid slower sales cycles in Europe and the Americas; it launched the CE-marked Gut Detective product in August 2025 exclusively for the UK practitioner market initially; operational enhancements drove gross margins to 67.7% for the six months ended 30 September 2025 through improved FoodPrint production yields and product mix, despite a 6% revenue decline to £3.9 million; and the company invested in new manufacturing machinery, a Laboratory Information Management System upgrade, IVDR compliance development, and website enhancements while suspending new My Health Tracker app onboarding.